title: [Anti-androgen withdrawal syndrome].
abstract: Since the mid-forties androgen deprivation is regarded the standard treatment of incurable prostate cancer. Antiandrogens can be given either as monotherapy or in combination with bilateral orchidectomy or gonadotropin-releasing-hormone analoga. Recently reports have been published that withdrawal of antiandrogens in patients with hormone-resistant prostate cancer caused reduction of PSA and clinical improvement. Thus, in patients who progress under maximal androgen blockade or antiandrogen-monotherapy the antiandrogen should first be withdrawn and-in case of monotherapy-be replaced by GnRH-analoga. In approximately 30-50% of the cases a reduction of serum-PSA can be expected lasting for approx. 6 months. In some patients an improvement of symptoms and objective remission is observed.
authors.affiliation: Urologische Klinik und Poliklinik, Technischen Universität München, Klinikum rechts der Isar.
authors.forename: J
authors.initials: J
authors.lastname: Breul
authors.forename: R
authors.initials: R
authors.lastname: Paul
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D003131:Combined Modality Therapy; D018450:Disease Progression; D005485:Flutamide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013375:Substance Withdrawal Syndrome / Q000097:blood*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D005485:Flutamide; D017430:Prostate-Specific Antigen